Whalesbook
### New Impurity Found in Compounded Tirzepatide Linked to Vitamin B12
Eli Lilly has revealed findings from its testing of compounded tirzepatide products, showing significant levels of a new impurity. This impurity forms when tirzepatide, the active ingredient in Zepbound and Mounjaro, reacts with vitamin B12. All ten samples tested from compounding pharmacies, medspas, and telehealth providers contained this impurity. The short- and long-term health effects of this substance are unknown. Lilly's chief medical officer, David Hyman, stated that its impact on the drug's interaction with GLP-1 and GIP receptors, potential toxicity, and immune reactions are not yet understood. Lilly also found other serious safety issues in compounded tirzepatide products, such as bacterial contamination and high endotoxin levels, which are not present in Lilly's FDA-approved medications.
### Lilly and FDA Target Compounders with Warnings and Lawsuits
This revelation is the latest move in Eli Lilly's ongoing campaign against drug compounders. The U.S. Food and Drug Administration (FDA) has also increased its oversight, sending 30 warning letters in early March 2026 to telehealth companies for making false or misleading claims about compounded GLP-1 drugs. The FDA consistently warns that compounded products do not undergo the same safety, effectiveness, or quality reviews as approved medications. Such products can carry unknown risks, especially when reactive substances are added without clinical testing. Lilly has filed numerous lawsuits against compounding pharmacies, wellness centers, and telehealth platforms for allegedly selling illegal copies of Zepbound and Mounjaro. These legal actions accuse these companies of deceptive practices, false advertising, and unlawful compounding that endangers patient safety by bypassing the FDA's strict approval process. The FDA had declared the tirzepatide shortage resolved in December 2024, officially ending permission for further compounding of the drug.
### Lilly Aims to Protect Market Share Amid GLP-1 Growth
Eli Lilly's strong stance against compounding is a strategic move in the fast-growing GLP-1 market, which is projected to reach $268.4 billion by 2030. While Novo Nordisk's semaglutide drugs (Ozempic, Wegovy) currently hold a large share, tirzepatide products are expected to grow the quickest. By highlighting safety risks from compounded alternatives, like the vitamin B12 impurity, Lilly aims to strengthen its market position. The company seeks to protect patient trust in its approved medications and maintain premium pricing, potentially limiting competition from cheaper compounded versions and safeguarding its research investments. Novo Nordisk also faces competitive pressure; its new drug CagriSema showed less weight loss efficacy than Lilly's tirzepatide in recent trials.
### Compounders Defend Practices, But Lilly Highlights Unknown Risks
Drug compounders argue their services are legal, allowing personalized treatments for specific patient needs or during shortages of branded drugs. They state that compounding fills critical gaps and offers customized formulas. Lilly, however, contends that adding substances like vitamin B12 without clinical trials or FDA oversight introduces unstudied risks. The company's lawsuits and public warnings are putting significant pressure on compounders. While Lilly benefits from greater market control, the ongoing legal and regulatory actions create a complex industry environment. A wider concern for the pharmaceutical sector is the potential for increased regulatory oversight that could affect innovation or pricing strategies broadly.
### GLP-1 Market Growth and Analyst Views on Lilly, Novo Nordisk
The GLP-1 market is poised for continued rapid expansion, fueled by growing demand for diabetes and obesity treatments and the expected introduction of new oral formulations. Eli Lilly (LLY) holds a strong analyst consensus, with a 'Strong Buy' rating and an average price target of around $1,175, suggesting a projected upside of over 23%. The company anticipates significant revenue growth for 2026. Novo Nordisk (NVO), a market leader, has a more neutral 'Hold' rating, with a modest price target and facing competitive pressures. The ongoing regulatory actions against compounded drugs point toward a more consolidated and regulated future for the GLP-1 market, likely benefiting major pharmaceutical companies like Eli Lilly and Novo Nordisk.